EUCTR2005-004689-18-DK进行中（未招募）不适用
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, 2-Arm Study to Investigate the Effect of Aprotinin on Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung Cancer or Esophageal Cancer - NA
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Bayer Inc.
- 入组人数
- 696
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects (men or non-pregnant women) 18 years of age and older.
- •Subjects requiring protocol specified oncological surgery.
- •Documented, signed, dated informed consent obtained prior to any study specific procedures being performed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects with previous exposure to aprotinin in the last 6 months. If the subject has undergone cardiac surgery in the previous 6 months, all attempts should be made to ascertain if aprotinin was administered during cardiac surgery. If no records are available, or if the subject received aprotinin, the subject should be excluded.
- •Subjects with a known or suspected allergy to aprotinin.
- •Subjects undergoing laparoscopic resection.
- •Subjects with sepsis.
- •Subjects with impaired renal function (serum creatinine >2.5 mg/dl or 221 micromoles/liter).
- •Subjects with a history of bleeding diathesis or known coagulation factor deficiency.
- •Subjects with failure of a major organ system or any active significant medical illness that in the opinion of the Investigator is likely to affect the subject’s ability to complete the study or precludes the subject’s participation in the study.
- •Subjects who refuse to receive allogenic blood products for religious or other reasons.
- •Subjects whose preoperative red blood cell volume is so low that a blood transfusion will have to be given perioperatively (pre-operative hematocrit or hemoglobin values < 24 % or < 8 g/dl, respectively).
- •Subjects with a history of deep vein thrombosis or pulmonary embolism.
- •Women who are pregnant, breastfeeding or women of childbearing potential in whom the possibility of pregnancy cannot be excluded by a negative serum pregnancy test at screening.
- •Women of childbearing potential who are not using a reliable method of contraception. Methods of contraception that are considered reliable are intrauterine devices (IUDs), birth control pills, hormonal implants/patches, and barrier contraception when used with spermicidal products.
- •Use of other antifibrinolytic agents e.g. aminocaproic acid or tranexamic acid.
- •Subjects on a chronic anti-coagulant treatment with vitamin k antagonists where it can not be discontinued presurgery for the surgical procedure.
- •Subjects on an investigational drug (i.e. not marketed) in the 30 days prior to screening or during the trial before the 6 week follow-up visit. Subjects involved in trials of marketed cancer therapy medications (including those approved for another indication) or combination with radiotherapy are allowed.
- •Subjects undergoing thoracoscopic resection or simple (single lobe) lobectomy as the planned procedure.
- •Subjects undergoing any palliative operation.
研究者
相似试验
进行中（未招募）
不适用
Treatment Resistant Depression study for RO4995819MedDRA version: 14.1Level: PTClassification code 10012378Term: DepressionSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 14.1Level: LLTClassification code 10025453Term: Major depressive disorder NOSSystem Organ Class: 10037175 - Psychiatric disordersMajor Depressive DisorderEUCTR2011-002160-24-ATF. Hoffmann-La Roche Ltd.340
进行中（未招募）
1 期
Efficacy, Safety, and Durability of Response of BMS-986165 versus Placebo and Active Comparator in Subjects with PsoriasisEUCTR2018-001925-24-GBBristol-Myers Squibb International Corporation1,000
进行中（未招募）
1 期
Phase 3 trial of PXT3003 in Charcot-Marie-Tooth (CMT) Type 1A patientsCharcot Marie Tooth Type 1AMedDRA version: 20.0Level: LLTClassification code 10008414Term: Charcot-Marie-Tooth diseaseSystem Organ Class: 100000004850EUCTR2020-004805-30-BEPharnext SCA387
进行中（未招募）
不适用
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled 12-week Pilot Exploratory Study to Evaluate the Efficacy and Safety of Teikoku Tulobuterol Tape (6 mg) in Adults with Bronchial AsthmaReversible airways obstruction in patients with AsthmaMedDRA version: 9.1Level: LLTClassification code 10062109Term: Reversible airways obstructionMedDRA version: 9.1Level: LLTClassification code 10006070Term: Br. asthmaEUCTR2007-004886-16-LTTeikoku Pharma USA, Inc.80
进行中（未招募）
1 期
Study to evaluate effectiveness and safety in subjects with moderate to severe PsoriasisEUCTR2016-002481-31-LVBristol-Myers Squibb International Corporation516